Aevolve Health Zurich Investor Presentation & Dinner
February 12th, 2020 @ 4:00pm Europe/Zurich
On Sale Until: Wednesday, February 12th 2020, 8:00 pm

Error! You must select at least one ticket to continue.
Error! Please select a date and time before continuing.
Available Selections

Accredited Investor Access Request

Not on Sale

No description.


More Info

Venue details will be shared with confirmed investors participating in Visionary's arranged meetings.

 

Industry: Digital Health, TeleMedicine, Blockchain

Visionary Member: Rogelio Santos, CEO and Mark Chester, COO of Aevolve AG (www.aevolve.health)

Highlights:

  • AEVOLVE is a protocol built using blockchain and utilizing our AVEX token to empower our e-commerce BioSphere medical innovation market place.
  • We connect patients directly to medical innovators and allow them to make a purchase of a coupon to the future treatment/innovation.
  • In turn the innovators get access to funds to complete the innovation.
  • The patient becomes the investor and has a 100% guarantee should the innovation not be completed for any reason.
  • In addition the patient has immediate access to an online marketplace where they can liquidate the coupon if they no longer require it.
  • Upon launch we have over 35,000 global physicians, over 100,000 patients and 6 medical innovations addressing disease areas including – Alzheimer’s, Type 1 & 2 Diabetes, ALS, Transplants, Cancer etc. and a strong pipeline to list over the coming years.
  • Our initial launch is with an exclusivity for the pre-sale of an FDA approved beta-amyloid reduction technology that will halt the progression of diseases such as Alzheimer’s.
  • This Amylex listing on the AEVOLVE platform is for 100,000 treatments at 10,000 AVEX per treatment – resulting in a 1bn marketplace revenue in year 1.
  • The AEVOLVE BioSphere platform will launch in April. We are conducting an investor round through the issuance of a ISIN Swiss Structured Product to qualified Swiss Investors.
  • The opportunity of the ISIN is to gain access to track the performance of AVEX at an opening price of $1. The AEVOLVE Tokenomics indicate a high expectation the Token price will be at least $5 based on the just the initial Amylex product sale.
  • In addition AEVOLVE is offering a 3rd party issued bond that will provide a 50% floor protection on any investment that exceeds 5m.


Currently Seeking: Seed stage investors into Swiss ISIN model